CN103073607A - 12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof - Google Patents
12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof Download PDFInfo
- Publication number
- CN103073607A CN103073607A CN2013100599032A CN201310059903A CN103073607A CN 103073607 A CN103073607 A CN 103073607A CN 2013100599032 A CN2013100599032 A CN 2013100599032A CN 201310059903 A CN201310059903 A CN 201310059903A CN 103073607 A CN103073607 A CN 103073607A
- Authority
- CN
- China
- Prior art keywords
- tetraene
- beta
- triketone
- compound
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 241001408435 Epigynum auritum Species 0.000 abstract description 9
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 3
- -1 androstane compound Chemical class 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010062016 Immunosuppression Diseases 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QZLYKIGBANMMBK-UGCZWRCOSA-N 5α-Androstane Chemical compound C([C@@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 QZLYKIGBANMMBK-UGCZWRCOSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004719 natural immunity Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 244000205574 Acorus calamus Species 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an androstane compound with high polyenoid oxidizability, i.e. 12[beta]-hydroxyandrostane-4,6,8(9), 13(14)-tetraene-3,11,16-triketone. The compound is extracted from epigynum auritum plants. Experiments prove that the compound provided by the invention has immunosuppressive activity.
Description
Technical field
The present invention relates to a kind of androstane of new polyenoid high oxidation degree, 12 beta-hydroxy androstanes-4,6 specifically, 8(9), and 13(14)-tetraene-3,11,16-3 ketone and as the application of immunosuppressive drug.
Background technology
Epigynum Auritum (
Epigynum auritum) be a kind of Apocynaceae Epigynum Auritum family Simao Calamus, originate in south of Yunnan, according to the result of study in our early stage, contain the C of more novel structure in the Epigynum Auritum
21Steroidal and other compound.Under the interest drive of finding the new drug lead compound, we have carried out a large amount of bioactivity screening experiments to these new compounds, find androstane (the 12 beta-hydroxy androstanes-4 of one of them high saturation high oxidation degree, 6,8(9), 13(14)-and tetraene-3,11, the 16-triketone) under the concentration of 40 μ g/mL, have immunosuppressive activity.
Immunosuppression refers to the restraining effect for immunne response, and immunosuppression can be caused by natural or human factor; The natural immunity suppresses to comprise natural immunity tolerance, and body may not produce immunne response to autologous tissue's composition.Artificial immunization is suppressed at and is commonly used to clinically to suppress the rejection that occurs after the organ transplantation, the graft versus host disease (GVH disease) that occurs after the treatment bone marrow transplantation, or the autoimmune disorders such as treatment rheumatoid arthritis, Crohn disease, generally can carry out immunosuppression by medicine.Autoimmune disorder mostly is greatly chronic or PD needs long-term prescription, and the shortcomings such as existing glucocorticosteroid (such as dexamethasone) and immunosuppressor long-term prescription ubiquity toxic side effect are large, use inconvenience.In recent years, clinically the demand of immunosuppression class medicine constantly increased, therefore, in the urgent need to developing the neotype immunosuppressant of a class high-efficiency low-toxicity, natural product is the important sources of immunosuppressor, triptolide is exactly the diterpenic lactone that contains epoxy of separating from trypterygine, is one of major ingredient of trypterygine performance immunosuppression and anti-inflammatory action.12 beta-hydroxy androstanes-4,6 provided by the invention, 8(9), 13(14)-tetraene-3,11,16-3 ketone and have not yet to see report as immunosuppressive drug.
Summary of the invention
The object of the present invention is to provide a kind of new 12 beta-hydroxy androstanes-4,6 of the androstane with pharmaceutical use, 8(9), 13(14)-tetraene-3,11, the 16-triketone, its structural formula is as follows:
Androstane 12 beta-hydroxy androstanes-4 of the present invention, 6,8(9), 13(14)-tetraene-3,11, the 16-triketone extracts from the Epigynum Auritum plant and obtains, extracting method comprises the steps: to get Epigynum Auritum complete stool plant, with alcohol steep 3-4 time, each 24h, concentration and recovery ethanol makes medicinal extract behind the filter cleaner, behind medicinal extract water suspendible, remove low polarity component with petroleum ether extraction first, extracting with ethyl acetate, carry out rough segmentation with macroporous adsorbent resin D101, is 20% with mass percent concentration respectively, 35% and 60% ethanol-water solution carries out wash-out, collect 60% alcohol-water elutriant, use 200-300 order silica gel mixed sample after concentrated, the dress post carries out column chromatography, carries out gradient elution take sherwood oil-acetone two-phase system as moving phase again, detect with tlc TLC, merge the elutriant of same composition, component 5 is wherein carried out positive reverse phase silica gel, the repeatedly column chromatography of gel Sephadex LH-20, the wash-out purifying, obtain 12 beta-hydroxy androstanes-4,6,8(9), 13(14)-tetraene-3,11,16-triketone.
Another object of the present invention is with 12 beta-hydroxy androstanes-4,6,8(9), and 13(14)-tetraene-3,11, the 16-triketone is applied in the preparation immunosuppressive drug.
The compounds of this invention 12 beta-hydroxy androstanes-4,6,8(9), 13(14)-tetraene-3,11,16-triketone is to the ConA(ConA) the Balb/c mice spleen lymphocytes proliferation that stimulates has obvious restraining effect, compared with the control group that does not add this compound significant difference (
p＜0.01).
Embodiment
Below by embodiment the present invention is described in further detail, but content of the present invention is not limited to this, method all according to a conventional method operations if no special instructions, the conventional commercial reagent of agents useful for same employing if no special instructions or the reagent that configures according to a conventional method in the present embodiment.
Embodiment 1:12 beta-hydroxy androstane-4,6,8(9), 13(14)-tetraene-3,11, the preparation of 16-triketone
Get Epigynum Auritum (
Epigynum auritum) complete stool plant drymeal 8.3kg, with alcohol steep 3 times, each 24h, concentration and recovery ethanol makes medicinal extract behind the filter cleaner, behind medicinal extract water suspendible, remove low polarity component with petroleum ether extraction first, extract with ethyl acetate again, collecting ethyl acetate extraction part 150g, carry out rough segmentation with macroporous adsorbent resin D101, is 20% with mass percent concentration respectively, 35% and 60% ethanol-water solution carries out wash-out, collect 60% alcohol-water elutriant, get 20 gram medicinal extract after concentrated, with 200-300 order silica gel mixed sample, dry column-packing carries out column chromatography, carry out gradient elution take sherwood oil-acetone (volume ratio is as 10:1-1:1) two-phase system as moving phase, detect with tlc (TLC), merge the elutriant of same composition, finally obtain 7 part: Fr1, Fr2, Fr3, Fr4, Fr5, Fr6, Fr7; The Fr5 part of sherwood oil-acetone (volume ratio 4:1-3:2) wash-out (3.5 gram) is used 200-300 order silica gel mixed sample, dry column-packing, carry out gradient elution take sherwood oil-acetone (volume ratio 4:1-3:2) two-phase system as moving phase, (TLC) detects with tlc, merges same composition; Cut to sherwood oil-acetone (3:1) wash-out of obtaining in the previous action, use again 200-300 order silica gel, carry out column chromatography take sherwood oil-acetone (3:1) as moving phase, at last, carry out the column chromatography of gel (Sephadex LH-20) take methyl alcohol as moving phase, carry out again the column chromatography of reverse phase silica gel (C18) as moving phase take methanol-water (4:1), obtain compound 12 beta-hydroxy androstanes-4 final the separation, 6,8(9), 13(14)-tetraene-3,11,16-triketone 3.5mg is new compound through identifying this compound.
Qualification result is as follows:
Formula I compound 12 beta-hydroxy androstanes-4,6,8(9), 13(14)-tetraene-3,11, the 16-triketone is brown ceramic powder, is soluble in methyl alcohol, pyridine etc.Optically-active [α]
D 20.0+ 535.20 (c 0.66, methyl alcohol);
1H NMR (C
5D
5N-
d 6 , 600Mz),
13C NMR (C
5D
5N-
d 6 , 150Mz) see Table 1; Positive ion ESI in
M/z311 molecular ion peak (base peak) occurs, and HR-ESI-MS syncaryon magnetic resonance spectrum is released corresponding molecular formula and is: C
19H
18O
4(M+H)
+Calculated value: 3 11.1283, error :+1.4967 ppm).
Resolve according to above spectral data, formula (
) chemical structural formula of compound is as follows:
Systematic naming method is: 12 beta-hydroxy androstanes-4,6,8(9), 13(14)-tetraene-3,11,16-triketone [12 β-Hydroxyandrosta-4,6,8 (9), 13 (14)-tetraene-3,11,16-trione], be a new natural organic-compound.
Table 1:12 beta-hydroxy androstane-4,6,8(9), 13(14)-tetraene-3,11, the 16-triketone
13C NMR and
1H NMR data
Embodiment 2:12 beta-hydroxy androstane-4,6,8(9), 13(14)-tetraene-3,11, the immunosuppression test experience of 16-triketone
(1) preparation of splenocyte suspension liquid
The bloodletting of healthy Balb/c eyeball of mouse causes death, and places 75% alcohol soaking disinfection 5 minutes, takes out, place aseptic pallet, the left side in super clean bench, picks up abdomen middle part fur with the tweezers of sterilizing up, make a kerf, cut off each layer of stomach wall with an other cover apparatus, with the 3rd cover apparatus spleen is taken out, remove fat and reticular tissue, put into the PBS(phosphate buffered saline buffer), flush away floats blood; Then the spleen tissue is moved in the plate that fills RPMI 1640 incomplete nutrient solutions, be cut into small pieces with scissors, spleen is ground in 200 order stainless steel meshs with the asepsis injector core, with on a small quantity repeatedly flushing of PBS, filtration obtains the individual cells suspension, cell suspension is inhaled and is abandoned supernatant liquor at 4 ℃ of centrifugal 5min of lower 1200rpm, adds 3mL erythrocyte cracked liquid (Tris-NH
4Cl) mixing leaves standstill and adds 10 mL PBS termination reactions behind the 2min, and centrifugal (1200rpm, 5min) removes supernatant, and precipitation is with 5mL PBS washed twice, and is centrifugal under the similarity condition.Precipitation suspends with RPMI 1640 complete culture solutions that 5mL contains 10% foetal calf serum; Expect that with 0.8% blue viable cell refuses to dye method counting, viable count is no less than 95%, adds the dilution of RPMI 1640 complete culture solutions, adjusts cell concn to 2 * 10
6About individual/mL.
(2) preparation of test liquid
Precision takes by weighing monomeric compound 2mg, adds an amount of DMSO dissolving, be diluted to desired concn with PBS before the loading, and so that the DMSO final concentration after the loading is no more than 0.1%.
(3) experiment grouping
Normal group: 100 μ L splenocyte suspensions+10 μ L RPMI, 1640 perfect mediums+10 μ LPBS
Model group: 100 μ L splenocyte suspensions+10 μ LConA (final concentration is 5 μ g/mL)+10 μ LPBS
Sample sets: 100 μ L splenocyte suspensions+10 μ LConA (final concentration is 5 μ g/mL)+10 μ L samples
In 96 orifice plates, every hole adds lymphocyte suspension (2 * 10
6Individual/mL) 100 μ L, ConA 10 μ L (final concentration is 5 μ g/mL), different concns reagent diluted chemical compound liquid 10 μ L (final concentration is respectively 10,20,40 μ g/mL), the pure and mild dexamethasone of Triptolide is also done respectively the concentration group of three correspondences, 1640 complete culture solutions (containing 10% foetal calf serum) of 10 μ L and the PBS polishing of 10 μ L are used respectively in the Normal group hole, each concentration group establish 5 parallel.
(4) cultivate: place 37 ℃, 5 % CO
2Cultivated 72 hours in the incubator.
(5) the CCK-8 method is measured cell OD value
Cultivate after 72 hours, add the CCK-8 reagent (the green skies) of 15 μ L in every hole, place 37 ℃, 5 % CO
2Continue in the incubator to cultivate after 4 hours, measure the light absorption value in every hole at the 450nm place with calculating cell proliferation situation, and be calculated as follows stimulation index (SI):
The SI(stimulation index)=be added with the OD value of a mitogen culture/the be not added with OD value of a mitogen culture
(6) data processing
Experimental data OD value adopts " mean number ± standard deviation " to represent, mathematical statistics and variance analysis work adopt Origin software to finish.
(7) experimental result
Table 2: the compounds of this invention is to the stimulation index of the Balb/c mice spleen lymphocytes proliferation of ConA stimulation
| ? | ? | ? | ? | ? | On average | SD | Significantly analyze |
| Model group | 2.463232 | 2.475971 | 2.278859 | 2.527638 | 2.436425 | 0.108673 | |
| Yp is low dense | 2.259042 | 2.310001 | 2.063345 | 2.031142 | 2.165882 | 0.139185 | 0.022107 |
| Dense among the yp | 2.582844 | 2.538962 | 2.523745 | 2.627079 | 2.568158 | 0.046591 | 0.067429 |
| The yp height is dense | 1.717602 | 1.788379 | 1.728219 | 1.765022 | 1.749805 | 0.032774 | 1.94E-05 |
12 beta-hydroxy androstanes-4,6,8(9), 13(14)-tetraene-3,11, the stimulation index of 16-triketone when concentration is 10,20,40 μ g/mL is respectively: 2.17,2.57,1.74; Significance analysis shows, the high density group compare with model group that there were significant differences (
p＜0.01).
The positive control result is:
Table 3: dexamethasone is to the stimulation index of the Balb/c mice spleen lymphocytes proliferation of ConA stimulation
| ? | ? | ? | ? | ? | On average | SD | Significantly analyze |
| Model group | 2.428613 | 2.305179 | 2.347667 | 2.693429 | 2.443722 | 0.174167 | ? |
| DSM is low | 1.289503 | 1.407076 | 1.267526 | 1.4785 | 1.360651 | 0.099629 | 3.74E-05 |
| Among the DSM | 1.094645 | 1.152883 | 1.150319 | 1.290601 | 1.172112 | 0.083438 | 1.18E-05 |
| DSM is high | 1.023222 | 1.058384 | 1.167167 | 0.97524 | 1.056003 | 0.081569 | 6.94E-06 |
Table 4: triptolide is to the stimulation index of the Balb/c mice spleen lymphocytes proliferation of ConA stimulation
| ? | ? | ? | ? | ? | On average | SD | Significantly analyze |
| Model group | 2.736473 | 2.904163 | 2.82178 | 2.675539 | 2.784489 | 0.099814 | ? |
| Tri is low | 1.090426 | 1.088476 | 1.045091 | 1.263479 | 1.121868 | 0.096699 | 3.5E-07 |
| Among the Tri | 1.024617 | 0.949059 | 1.017793 | 1.200107 | 1.047894 | 0.107059 | 3.68E-07 |
| Tri is high | 0.985132 | 0.980257 | 0.948084 | 1.036804 | 0.987569 | 0.036709 | 4.47E-08 |
The stimulation index of triptolide when concentration is 10,20,40 μ g/mL is respectively: 1.12,1.05,0.99; Significance analysis shows, each concentration group compare with model group that there were significant differences (
p＜0.01);
The stimulation index of dexamethasone when concentration is 10,20,40 μ g/mL is respectively: 1.36,1.17,1.06; Significance analysis shows, each concentration group compare with model group that there were significant differences (
p＜0.01);
Can find out according to experimental result: 12 beta-hydroxy androstanes-4,6,8(9), 13(14)-and tetraene-3,11, the 16-3 ketone has immunosuppressive activity when concentration is 40 μ g/mL.
Claims (2)
1. structural formula is suc as formula 12 beta-hydroxy androstanes-4,6 shown in the I, 8(9), and 13(14)-tetraene-3,11, the 16-triketone:
Formula I.
2. the described 12 beta-hydroxy androstanes-4,6 of claim 1,8(9), 13(14)-tetraene-3,11, the application of 16-triketone in the preparation immunosuppressive drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310059903.2A CN103073607B (en) | 2013-02-26 | 2013-02-26 | 12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310059903.2A CN103073607B (en) | 2013-02-26 | 2013-02-26 | 12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103073607A true CN103073607A (en) | 2013-05-01 |
| CN103073607B CN103073607B (en) | 2014-09-03 |
Family
ID=48150324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310059903.2A Expired - Fee Related CN103073607B (en) | 2013-02-26 | 2013-02-26 | 12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103073607B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105732755A (en) * | 2016-02-19 | 2016-07-06 | 泰州职业技术学院 | 3beta-hydroxyl-16-aryl androstane-5(6),8(14),15(16)-triene-17-ketone |
| CN107056868A (en) * | 2017-03-24 | 2017-08-18 | 昆明理工大学 | Epigynum Auritum pregnane glucoside compound and its application |
| CN107056855A (en) * | 2017-03-24 | 2017-08-18 | 昆明理工大学 | A kind of 16,17 open loop pregnane glycoside compounds and its application |
| CN108191937A (en) * | 2018-01-02 | 2018-06-22 | 昆明理工大学 | A kind of polyenoid androstane ketone compound and its application |
| CN108822175A (en) * | 2018-04-26 | 2018-11-16 | 昆明理工大学 | 3,16- androstenedione class compound and its application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000428A1 (en) * | 1992-06-24 | 1994-01-06 | Schering Aktiengesellschaft | Derivatives in the vitamin d series modified at the 20 position, a method of preparing such derivatives, intermediates used in this method, pharmaceutical preparations containing the derivatives and their use in the preparation of drugs |
| CN1100101A (en) * | 1993-05-28 | 1995-03-15 | 日本化药株式会社 | 14alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same |
| CN1563070A (en) * | 2004-03-19 | 2005-01-12 | 复旦大学 | Androstane 4 ene-3 beta, 6 beta, 17 beta-trihydric alcohol and preparation method |
-
2013
- 2013-02-26 CN CN201310059903.2A patent/CN103073607B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994000428A1 (en) * | 1992-06-24 | 1994-01-06 | Schering Aktiengesellschaft | Derivatives in the vitamin d series modified at the 20 position, a method of preparing such derivatives, intermediates used in this method, pharmaceutical preparations containing the derivatives and their use in the preparation of drugs |
| CN1100101A (en) * | 1993-05-28 | 1995-03-15 | 日本化药株式会社 | 14alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and process for producing same |
| CN1563070A (en) * | 2004-03-19 | 2005-01-12 | 复旦大学 | Androstane 4 ene-3 beta, 6 beta, 17 beta-trihydric alcohol and preparation method |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105732755A (en) * | 2016-02-19 | 2016-07-06 | 泰州职业技术学院 | 3beta-hydroxyl-16-aryl androstane-5(6),8(14),15(16)-triene-17-ketone |
| CN105732755B (en) * | 2016-02-19 | 2017-05-31 | 泰州职业技术学院 | The aryl androstane 5 (6), 8 (14) of 3 β hydroxyls 16, the ketone of 15 (16) triolefin 17 |
| CN107056868A (en) * | 2017-03-24 | 2017-08-18 | 昆明理工大学 | Epigynum Auritum pregnane glucoside compound and its application |
| CN107056855A (en) * | 2017-03-24 | 2017-08-18 | 昆明理工大学 | A kind of 16,17 open loop pregnane glycoside compounds and its application |
| CN108191937A (en) * | 2018-01-02 | 2018-06-22 | 昆明理工大学 | A kind of polyenoid androstane ketone compound and its application |
| CN108191937B (en) * | 2018-01-02 | 2020-09-25 | 昆明理工大学 | Polyene androsterone compound and application thereof |
| CN108822175A (en) * | 2018-04-26 | 2018-11-16 | 昆明理工大学 | 3,16- androstenedione class compound and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103073607B (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103073607B (en) | 12[beta]-hydroxyandrostane-4,6,8(9),13(14)-tetraene-3,11,16-triketone and application thereof | |
| CN103073608B (en) | Androstane-4, 6, 8 (9), 13 (14)-tetraene-3, 11, 16-triketone and application thereof | |
| CN103816296B (en) | Callicarpa total glycoside extract and preparation method and application thereof | |
| US20040162246A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN103340983A (en) | Lycium ruthenicum fruit extract as well as preparation method and application thereof | |
| CN106491680B (en) | A Chinese medicinal composition for preventing or treating senile dementia, and its preparation method | |
| WO2024114248A1 (en) | Citrus fruit extract, and preparation method therefor and use thereof | |
| CN104027362B (en) | Antrodia camphorata extract for treating lung cancer and preparation method thereof | |
| CN102335348A (en) | Gastrodia elata plant extract for preventing parkinson disease and preparation method thereof | |
| CN108619316A (en) | Active component of matrimony vine young tea leaves and preparation method thereof, application | |
| CN104873570A (en) | Extracting and purifying method for prunella vulgaris total flavonoids and application of prunella vulgaris total flavonoids | |
| CN103977391B (en) | The preparation method of a kind of Xiao chaihu capsule and application | |
| CN101732440A (en) | Raspberry extract and raspberry element obtain by separation thereof and application thereof | |
| CN108524668B (en) | Preparation method of Chinese wolfberry extract with repairing and treating effects on drug-induced liver injury | |
| CN114891131A (en) | Extraction and purification process of nostoc commune polysaccharide | |
| KR102091528B1 (en) | Composition for treating liver diseases contain ginseng extracts | |
| CN104288238B (en) | A kind of medicine for the treatment of intestinal irritable syndrome and preparation method thereof and detection method | |
| CN109876021B (en) | Preparation method of Lyophyllum decastes extract rich in polyacetylene compounds and its blood sugar lowering application | |
| CN107847525A (en) | Composition and method for inhibition of histone deacetylase | |
| CN108727322B (en) | Phenethyl chromone dimer, preparation method thereof, pharmaceutical composition and application | |
| CN105326872A (en) | Preparation method for herba patriniae extract with therapeutical effect on ulcerative colitis | |
| CN104547148A (en) | Hedyotis diffusa extract used for preventing and treating senile dementia and preparation method of hedyotis diffusa extract | |
| CN106860771B (en) | Preparation method of rhizoma gastrodiae refined component, rhizoma gastrodiae refined component and application | |
| CN108619179A (en) | Geranium extract and its medical usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140903 Termination date: 20160226 |